A medical device company with a tissue glue technology for tummy tucks and other applications has raised more than $8 million in convertible notes as part of a series D round to expand its marketing efforts for the CE Mark-approved device and complete clinical trials in the U.S. Patrick Daly, president and CEO of Cohera […]
Fresh off receiving European regulatory approval for its tissue glue for tummy-tuck surgeries, Cohera Medical has raised more equity toward a series C round that could reach as high as $28 million. The company had been planning for $25 million for the round, but substantial investor interest may push the number higher, CEO Patrick Daly […]
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Cohera Medical Inc. has raised $12.7 million in investment funding, nudging past the halfway point to what it hopes will be a $25 million Series C round. The funding comes in the form of convertible notes and was raised from existing investors, CEO Patrick Daly said. Daly expects Cohera’s 28 existing investors to contribute a […]
Cohera's lead product is called TissuGlu and is designed to minimize fluid accumulation and other problems associated with abdominoplasty, or "tummy-tuck" surgeries.